Hospital
Christiana Care Health Services, INC.
Christiana Care Health Services, INC. was paid $99.19M by Medicaid between Jan 2018 and Dec 2024, across 556 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoCHRISTIANA CARE HEALTH SERVICES, INC.
WILMINGTON, DE 19801
WILMINGTON, DE 19801
33aNPI1134194038assigned 02/22/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$99.19M
24GClaims2,866,197
24DCodes billed556
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MCMURRAY, ROBERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 759,725 | $5.71M | |
| 2019 | 623,069 | $17.14M | |
| 2020 | 405,998 | $31.56M | |
| 2021 | 207,871 | $11.06M | |
| 2022 | 324,616 | $13.72M | |
| 2023 | 353,729 | $12.83M | |
| 2024incomplete | 191,189 | $7.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 183,443 | 127,879 | $17.53M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.2% | 100,839 | 70,587 | $8.09M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.5% | 63,078 | 46,103 | $6.44M |
| 41899 | Unlisted procedure, dentoalveolar structures | 5.8% | 2,744 | 2,131 | $5.75M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.3% | 33,940 | 25,444 | $3.32M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.3% | 42,154 | 31,096 | $3.31M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 2.8% | 583 | 385 | $2.75M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.7% | 5,974 | 4,646 | $2.71M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 32,858 | 7,963 | $2.39M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.2% | 21,460 | 13,280 | $2.15M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 14,623 | 11,615 | $1.53M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 235,265 | 150,451 | $1.41M |
544 more codes
| J2505 | Injection, pegfilgrastim, 6 mg | 1.3% | 341 | $1.30M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.3% | 19,689 | $1.26M |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 82,530 | $1.08M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.0% | 77,250 | $1.04M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 25,543 | $984K |
| 93971 | <1% | 4,215 | $895K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 20,528 | $893K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 28,251 | $841K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 28,252 | $837K |
| G0378 | Hospital observation service, per hour | <1% | 8,488 | $773K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 21,231 | $725K |
| 80053 | Comprehensive metabolic panel | <1% | 53,925 | $700K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 8,386 | $689K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 17,602 | $688K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 758 | $682K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 42,673 | $675K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 16,507 | $665K |
| 93970 | <1% | 2,124 | $637K | |
| 80051 | <1% | 61,281 | $603K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 54,610 | $537K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,930 | $527K |
| 87536 | <1% | 8,607 | $491K | |
| 97161 | <1% | 5,289 | $467K | |
| 77386 | <1% | 740 | $458K | |
| 84484 | <1% | 38,218 | $444K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,729 | $438K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 15,572 | $430K |
| 87631 | <1% | 4,306 | $414K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,855 | $398K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,585 | $393K |
| 76801 | <1% | 7,075 | $372K | |
| 76830 | Ultrasound, transvaginal | <1% | 7,746 | $348K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 8,221 | $348K |
| 96367 | <1% | 3,028 | $313K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 4,887 | $312K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 8,567 | $312K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,355 | $306K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 519 | $293K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 5,717 | $291K |
| J2704 | Injection, propofol, 10 mg | <1% | 21,333 | $289K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,278 | $276K |
| 93458 | <1% | 268 | $259K | |
| 80061 | Lipid panel | <1% | 23,753 | $253K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 6,186 | $249K |
| 80076 | <1% | 18,222 | $240K | |
| 36430 | <1% | 1,664 | $239K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 6,906 | $238K |
| 90715 | <1% | 4,215 | $238K | |
| 77412 | <1% | 1,863 | $235K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 719 | $233K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 258 | $226K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 28,525 | $222K |
| 82565 | <1% | 70,178 | $214K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,447 | $202K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 23,315 | $190K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 27,860 | $190K |
| 83690 | <1% | 26,144 | $190K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 29,263 | $187K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 23,449 | $172K |
| J0897 | Injection, denosumab, 1 mg | <1% | 203 | $166K |
| 84520 | <1% | 63,142 | $166K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,255 | $165K |
| 82947 | <1% | 64,500 | $162K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,731 | $160K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 578 | $159K |
| 95886 | <1% | 1,019 | $156K | |
| 83605 | <1% | 13,276 | $152K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,202 | $151K |
| 83735 | <1% | 22,183 | $147K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 3,808 | $147K |
| 71250 | <1% | 3,500 | $146K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 8,704 | $145K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,041 | $134K |
| 87660 | <1% | 10,471 | $134K | |
| 87480 | <1% | 10,461 | $134K | |
| 87510 | <1% | 10,445 | $133K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 8,225 | $133K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,202 | $132K |
| 82728 | <1% | 11,921 | $131K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 17,112 | $128K |
| 97116 | <1% | 4,336 | $123K | |
| 86803 | <1% | 9,281 | $119K | |
| 47562 | <1% | 207 | $118K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,016 | $118K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,510 | $117K |
| 93880 | <1% | 731 | $114K | |
| 70498 | <1% | 1,160 | $113K | |
| 84703 | <1% | 12,957 | $112K | |
| 93798 | <1% | 2,219 | $111K | |
| 88307 | <1% | 1,603 | $109K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 993 | $108K |
| 97165 | <1% | 1,488 | $108K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,287 | $105K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 4,137 | $105K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 10,051 | $103K |
| 93000 | <1% | 4,946 | $102K | |
| 94726 | <1% | 1,305 | $102K | |
| 81001 | <1% | 34,371 | $102K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 1,036 | $100K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,414 | $100K |
| 70491 | <1% | 1,390 | $96K | |
| 93308 | <1% | 328 | $94K | |
| 92526 | <1% | 1,530 | $91K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,233 | $89K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,340 | $89K |
| 76642 | <1% | 3,301 | $88K | |
| 11981 | <1% | 309 | $88K | |
| 93922 | <1% | 642 | $86K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 388 | $86K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 18,418 | $86K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 392 | $85K |
| 84702 | <1% | 7,170 | $84K | |
| 86360 | <1% | 3,981 | $83K | |
| 87077 | <1% | 8,490 | $83K | |
| 97162 | <1% | 1,032 | $82K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,020 | $80K |
| 85027 | <1% | 16,854 | $79K | |
| 86850 | <1% | 5,918 | $79K | |
| 76536 | <1% | 1,949 | $77K | |
| 83880 | <1% | 5,114 | $76K | |
| 80050 | General health panel | <1% | 3,380 | $76K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 18,874 | $74K |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 1,074 | $73K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,915 | $73K |
| 87040 | <1% | 2,437 | $72K | |
| 73630 | <1% | 7,105 | $71K | |
| 86920 | <1% | 1,231 | $68K | |
| 94729 | <1% | 1,494 | $68K | |
| 94060 | <1% | 1,423 | $68K | |
| 10060 | <1% | 1,552 | $66K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 964 | $66K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 5,207 | $65K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,172 | $64K |
| C1769 | Guide wire | <1% | 3,520 | $63K |
| 83550 | <1% | 7,873 | $63K | |
| 76770 | <1% | 1,749 | $62K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 3,715 | $61K |
| 88341 | <1% | 1,096 | $61K | |
| 93015 | <1% | 958 | $60K | |
| 73130 | <1% | 5,111 | $59K | |
| 82607 | <1% | 6,155 | $59K | |
| 74183 | <1% | 534 | $59K | |
| 73560 | <1% | 6,141 | $59K | |
| 70544 | <1% | 896 | $59K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,697 | $58K |
| 86480 | <1% | 2,285 | $58K | |
| 77334 | <1% | 576 | $57K | |
| 72141 | <1% | 897 | $57K | |
| 87186 | <1% | 7,478 | $56K | |
| 88342 | <1% | 1,764 | $56K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 170 | $56K |
| 80055 | <1% | 1,787 | $56K | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 1,255 | $55K |
| 96376 | <1% | 3,966 | $55K | |
| 72100 | <1% | 4,476 | $55K | |
| 83540 | <1% | 8,399 | $53K | |
| 87653 | <1% | 2,488 | $53K | |
| 84439 | <1% | 8,384 | $53K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 5,056 | $49K |
| 97166 | <1% | 678 | $48K | |
| 59025 | Fetal non-stress test | <1% | 1,690 | $47K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 179 | $46K |
| 81003 | <1% | 21,244 | $46K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,997 | $45K |
| 87522 | Neg quan hep c or qual rna | <1% | 2,156 | $44K |
| 19318 | <1% | 13 | $44K | |
| 85379 | <1% | 4,461 | $43K | |
| 82803 | <1% | 4,541 | $43K | |
| 80069 | <1% | 2,999 | $43K | |
| 87340 | <1% | 4,149 | $42K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 22,442 | $41K |
| 87070 | <1% | 4,118 | $41K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,746 | $41K |
| 70496 | <1% | 653 | $41K | |
| 87641 | <1% | 1,662 | $41K | |
| 82948 | <1% | 17,508 | $40K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,374 | $40K |
| 73030 | <1% | 4,227 | $40K | |
| 86901 | <1% | 7,488 | $40K | |
| 58300 | <1% | 199 | $40K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 600 | $39K |
| 86706 | <1% | 3,506 | $39K | |
| 82746 | <1% | 4,098 | $39K | |
| 86900 | <1% | 7,461 | $39K | |
| C1876 | Stent, non-coated/non-covered, with delivery system | <1% | 70 | $39K |
| 12001 | <1% | 960 | $39K | |
| 85610 | <1% | 10,800 | $38K | |
| 86592 | <1% | 12,804 | $38K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,180 | $37K |
| 95816 | <1% | 245 | $36K | |
| 87075 | <1% | 1,845 | $36K | |
| 82043 | <1% | 5,616 | $36K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 10,777 | $35K |
| 77300 | <1% | 522 | $34K | |
| 83615 | <1% | 8,110 | $33K | |
| 95819 | <1% | 155 | $33K | |
| 84460 | <1% | 10,312 | $33K | |
| 84450 | <1% | 10,071 | $31K | |
| 93325 | <1% | 245 | $31K | |
| 96417 | <1% | 1,483 | $31K | |
| 88312 | <1% | 1,213 | $31K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,502 | $31K |
| 73600 | <1% | 3,174 | $30K | |
| 85730 | <1% | 5,126 | $30K | |
| 70480 | <1% | 440 | $30K | |
| 77336 | <1% | 1,431 | $30K | |
| Q3014 | Telehealth originating site facility fee | <1% | 5,560 | $29K |
| 87088 | <1% | 7,048 | $29K | |
| 82784 | <1% | 1,620 | $28K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,261 | $28K |
| 12011 | <1% | 709 | $28K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,303 | $28K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,772 | $27K |
| 86140 | <1% | 4,957 | $26K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 218 | $26K |
| 58558 | <1% | 91 | $25K | |
| 92610 | <1% | 482 | $25K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 8,670 | $25K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 229 | $24K |
| 72170 | <1% | 2,798 | $24K | |
| 92523 | <1% | 362 | $24K | |
| 70486 | <1% | 544 | $23K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,519 | $23K |
| 74175 | <1% | 256 | $22K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 534 | $22K |
| 82247 | <1% | 7,090 | $22K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,239 | $22K |
| 82570 | <1% | 3,831 | $22K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 275 | $21K |
| 49083 | <1% | 93 | $21K | |
| 90937 | <1% | 504 | $21K | |
| 85651 | <1% | 5,811 | $21K | |
| 83970 | <1% | 1,045 | $20K | |
| 84075 | <1% | 6,360 | $20K | |
| 82731 | <1% | 471 | $20K | |
| 88304 | <1% | 1,328 | $20K | |
| 80074 | <1% | 833 | $20K | |
| 12002 | <1% | 523 | $19K | |
| 19083 | <1% | 134 | $19K | |
| 96415 | <1% | 1,826 | $19K | |
| 70547 | <1% | 336 | $19K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 246 | $18K |
| 29125 | <1% | 598 | $18K | |
| 87205 | <1% | 3,962 | $18K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 643 | $18K |
| 83883 | <1% | 837 | $18K | |
| 84153 | <1% | 935 | $18K | |
| 88360 | <1% | 493 | $18K | |
| 88173 | <1% | 774 | $18K | |
| 72197 | <1% | 114 | $17K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,077 | $17K |
| A4648 | Tissue marker, implantable, any type, each | <1% | 223 | $17K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,065 | $17K |
| 82550 | <1% | 2,470 | $17K | |
| 82378 | <1% | 589 | $17K | |
| S5105 | Day care services, center-based; services not included in program fee, per diem | <1% | 7,552 | $16K |
| 74178 | <1% | 183 | $16K | |
| 76870 | <1% | 607 | $16K | |
| 72131 | <1% | 348 | $15K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 63 | $15K |
| 85046 | <1% | 2,750 | $15K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,940 | $15K |
| 83020 | <1% | 1,680 | $15K | |
| 73610 | <1% | 1,456 | $15K | |
| 82105 | <1% | 1,084 | $14K | |
| 84100 | <1% | 4,883 | $14K | |
| 77290 | <1% | 123 | $14K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 283 | $14K |
| 88142 | <1% | 952 | $14K | |
| OP250 | <1% | 2,029 | $13K | |
| 84134 | <1% | 767 | $13K | |
| 86704 | <1% | 1,410 | $13K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 256 | $13K |
| 84403 | <1% | 768 | $13K | |
| 73590 | <1% | 1,397 | $13K | |
| 74174 | <1% | 50 | $12K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 402 | $12K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,193 | $12K |
| 72158 | <1% | 96 | $12K | |
| 73140 | <1% | 1,088 | $12K | |
| 93224 | <1% | 15 | $12K | |
| 88313 | <1% | 539 | $11K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 587 | $11K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 101 | $11K |
| 85018 | <1% | 6,190 | $11K | |
| 85384 | <1% | 1,101 | $11K | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 647 | $11K |
| 73090 | <1% | 1,183 | $11K | |
| 86334 | <1% | 581 | $11K | |
| 84146 | <1% | 570 | $10K | |
| 74018 | <1% | 1,644 | $10K | |
| 86235 | <1% | 179 | $10K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,336 | $10K |
| 77080 | <1% | 766 | $10K | |
| 96411 | <1% | 779 | $10K | |
| 72040 | <1% | 1,075 | $10K | |
| 84156 | <1% | 3,671 | $10K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 248 | $10K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 122 | $10K |
| 73110 | <1% | 815 | $10K | |
| 71271 | <1% | 131 | $10K | |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg | <1% | 14 | $9K |
| 0002A | <1% | 246 | $9K | |
| 86038 | <1% | 1,641 | $9K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 272 | $9K |
| 80164 | <1% | 756 | $9K | |
| 72156 | <1% | 90 | $9K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,833 | $9K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 68 | $9K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,441 | $9K |
| 52000 | <1% | 32 | $9K | |
| S9128 | Speech therapy, in the home, per diem | <1% | 118 | $9K |
| 72070 | <1% | 849 | $8K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,418 | $8K |
| 85670 | <1% | 909 | $8K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 23 | $8K |
| 76604 | <1% | 130 | $8K | |
| 78582 | <1% | 188 | $8K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,476 | $8K |
| 83001 | <1% | 466 | $8K | |
| 86708 | <1% | 697 | $8K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 4,011 | $8K |
| 84165 | <1% | 930 | $8K | |
| 76882 | <1% | 453 | $8K | |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | <1% | 283 | $8K |
| 73070 | <1% | 918 | $8K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 24,209 | $8K |
| 82670 | <1% | 149 | $7K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 139 | $7K |
| 83516 | <1% | 551 | $7K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 529 | $7K |
| 87506 | <1% | 154 | $7K | |
| 82248 | <1% | 2,264 | $7K | |
| 97014 | <1% | 723 | $7K | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 51 | $7K |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 163 | $7K |
| 84480 | <1% | 707 | $7K | |
| 97163 | <1% | 146 | $7K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,263 | $7K |
| 96416 | <1% | 189 | $7K | |
| 83655 | <1% | 897 | $7K | |
| 84550 | <1% | 1,788 | $7K | |
| 49450 | <1% | 15 | $6K | |
| 0223U | <1% | 60 | $6K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 2,023 | $6K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 272 | $6K |
| 73562 | <1% | 758 | $6K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,739 | $6K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 250 | $6K |
| 29515 | <1% | 264 | $6K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 238 | $6K |
| 87102 | <1% | 1,022 | $6K | |
| 94618 | <1% | 220 | $5K | |
| 86618 | <1% | 897 | $5K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 23 | $5K |
| 71101 | <1% | 556 | $5K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 19 | $5K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 3,060 | $5K |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 201 | $5K |
| 93296 | <1% | 761 | $5K | |
| 88185 | <1% | 65 | $5K | |
| 90732 | <1% | 237 | $5K | |
| 86300 | <1% | 442 | $5K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 283 | $4K |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 255 | $4K |
| 95910 | <1% | 12 | $4K | |
| J2323 | Injection, natalizumab, 1 mg | <1% | 121 | $4K |
| 87634 | <1% | 793 | $4K | |
| 0001A | <1% | 127 | $4K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 443 | $4K |
| 74021 | <1% | 541 | $4K | |
| 73700 | <1% | 45 | $4K | |
| 77280 | <1% | 39 | $4K | |
| 94664 | <1% | 608 | $4K | |
| 94010 | <1% | 44 | $4K | |
| 82150 | <1% | 473 | $4K | |
| 73552 | <1% | 605 | $3K | |
| 73060 | <1% | 381 | $3K | |
| 97750 | <1% | 13 | $3K | |
| 76937 | <1% | 651 | $3K | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 107 | $3K |
| 87902 | <1% | 122 | $3K | |
| T1027 | Family training and counseling for child development, per 15 minutes | <1% | 200 | $3K |
| 87529 | <1% | 34 | $3K | |
| 86160 | <1% | 149 | $3K | |
| 82140 | <1% | 456 | $3K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 745 | $3K |
| 87081 | <1% | 1,026 | $3K | |
| 84436 | <1% | 656 | $3K | |
| 82533 | <1% | 178 | $3K | |
| 86200 | <1% | 289 | $3K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 959 | $3K |
| 87563 | <1% | 132 | $2K | |
| 90686 | <1% | 833 | $2K | |
| 86787 | <1% | 344 | $2K | |
| 77295 | <1% | 25 | $2K | |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 49 | $2K |
| 83002 | <1% | 158 | $2K | |
| 74181 | <1% | 33 | $2K | |
| 87254 | <1% | 273 | $2K | |
| 86430 | <1% | 910 | $2K | |
| 96523 | <1% | 94 | $2K | |
| 97113 | <1% | 99 | $2K | |
| 96368 | <1% | 158 | $2K | |
| 78306 | <1% | 27 | $2K | |
| 82330 | <1% | 318 | $2K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 15 | $2K |
| 97542 | <1% | 15 | $2K | |
| 87015 | <1% | 587 | $2K | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 231 | $2K |
| 97602 | <1% | 21 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 134 | $2K |
| 82977 | <1% | 582 | $2K | |
| 73100 | <1% | 232 | $2K | |
| 85347 | <1% | 82 | $2K | |
| 88112 | <1% | 208 | $2K | |
| 0012A | <1% | 46 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,939 | $2K |
| 94660 | <1% | 594 | $2K | |
| 82985 | <1% | 107 | $2K | |
| 82232 | <1% | 40 | $1K | |
| 84295 | <1% | 664 | $1K | |
| 74220 | <1% | 43 | $1K | |
| 80197 | <1% | 267 | $1K | |
| 87517 | <1% | 271 | $1K | |
| A9558 | Xenon xe-133 gas, diagnostic, per 10 millicuries | <1% | 202 | $1K |
| 12013 | <1% | 28 | $1K | |
| 85014 | <1% | 1,261 | $1K | |
| 83921 | <1% | 174 | $1K | |
| 84132 | <1% | 816 | $1K | |
| 36561 | <1% | 26 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 108 | $1K |
| A0425 | Ground mileage, per statute mile | <1% | 85 | $1K |
| J9310 | Injection, rituximab, 100 mg | <1% | 17 | $1K |
| 70360 | <1% | 307 | $1K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,687 | $1K |
| 51798 | <1% | 245 | $1K | |
| 92611 | <1% | 60 | $1K | |
| 74230 | <1% | 101 | $1K | |
| 83520 | <1% | 80 | $1K | |
| 83010 | <1% | 442 | $1K | |
| 72050 | <1% | 90 | $965.19 | |
| 80177 | <1% | 159 | $899.88 | |
| 86039 | <1% | 392 | $842.56 | |
| 82024 | <1% | 14 | $830.89 | |
| 88184 | <1% | 190 | $810.29 | |
| 87640 | <1% | 51 | $808.83 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 121 | $778.04 |
| 89050 | <1% | 149 | $777.09 | |
| 86705 | <1% | 61 | $730.71 | |
| 86256 | <1% | 15 | $729.18 | |
| 82172 | <1% | 259 | $597.18 | |
| 86304 | <1% | 13 | $568.03 | |
| 82677 | <1% | 49 | $566.16 | |
| 82040 | <1% | 128 | $537.46 | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 42 | $520.40 |
| 82374 | <1% | 160 | $446.79 | |
| 82435 | <1% | 161 | $438.59 | |
| 86593 | <1% | 76 | $418.92 | |
| 87147 | <1% | 325 | $414.82 | |
| 86336 | <1% | 49 | $403.92 | |
| C1758 | Catheter, ureteral | <1% | 45 | $355.59 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 58 | $349.16 |
| 82652 | <1% | 52 | $341.27 | |
| 80178 | <1% | 57 | $316.00 | |
| 36410 | <1% | 248 | $305.31 | |
| 81025 | <1% | 86 | $279.39 | |
| 96377 | <1% | 51 | $266.13 | |
| 84155 | <1% | 85 | $261.17 | |
| 82951 | <1% | 54 | $258.57 | |
| 90662 | <1% | 618 | $254.94 | |
| 84300 | <1% | 56 | $250.03 | |
| OP270 | <1% | 35 | $245.12 | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 25 | $245.09 |
| G0009 | Administration of pneumococcal vaccine | <1% | 494 | $233.84 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 54 | $232.60 |
| 82310 | <1% | 104 | $220.82 | |
| 86308 | <1% | 42 | $211.72 | |
| 93017 | <1% | 217 | $205.53 | |
| 77012 | <1% | 49 | $202.42 | |
| 80047 | <1% | 77 | $195.31 | |
| 87116 | <1% | 57 | $167.17 | |
| 82962 | <1% | 578 | $162.59 | |
| 86696 | <1% | 13 | $153.46 | |
| 72220 | <1% | 18 | $152.27 | |
| 73660 | <1% | 59 | $151.25 | |
| 73501 | <1% | 22 | $149.88 | |
| 73521 | <1% | 73 | $149.28 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 54 | $147.05 |
| 88172 | <1% | 58 | $141.97 | |
| 73221 | <1% | 20 | $137.37 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 1,353 | $127.01 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 1,426 | $126.99 |
| 88311 | <1% | 91 | $116.65 | |
| 86695 | <1% | 13 | $104.63 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 131 | $104.18 |
| 88300 | <1% | 97 | $100.50 | |
| 86147 | <1% | 14 | $91.16 | |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 569 | $89.39 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 571 | $89.37 |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 37 | $83.99 |
| 81002 | <1% | 214 | $83.28 | |
| 82164 | <1% | 51 | $81.03 | |
| 86762 | <1% | 57 | $66.07 | |
| 87176 | <1% | 21 | $57.51 | |
| 87493 | <1% | 51 | $47.18 | |
| 93923 | <1% | 17 | $45.64 | |
| 86146 | <1% | 14 | $45.54 | |
| 87206 | <1% | 54 | $41.61 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 18 | $32.31 |
| 77091 | <1% | 29 | $29.47 | |
| 84478 | <1% | 46 | $18.75 | |
| 86870 | <1% | 32 | $15.00 | |
| 86709 | <1% | 19 | $13.90 | |
| 90688 | <1% | 168 | $6.74 | |
| 91300 | <1% | 366 | $0.74 | |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 23 | $0.57 |
| 91301 | <1% | 53 | $0.10 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 560 | $0.09 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | <1% | 367 | $0.05 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 370 | $0.05 |
| G8989 | Self care functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 155 | $0.02 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | <1% | 232 | $0.02 |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 21 | $0.01 |
| 90682 | 0% | 18 | $0.00 | |
| 72114 | 0% | 51 | $0.00 | |
| 84481 | 0% | 18 | $0.00 | |
| C1788 | Port, indwelling (implantable) | 0% | 26 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 94 | $0.00 |
| 10022 | 0% | 17 | $0.00 | |
| 94727 | 0% | 12 | $0.00 | |
| C1729 | Catheter, drainage | 0% | 21 | $0.00 |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 0% | 13 | $0.00 |
| 76942 | 0% | 16 | $0.00 | |
| 95811 | 0% | 16 | $0.00 | |
| 86225 | 0% | 70 | $0.00 | |
| 64400 | 0% | 17 | $0.00 | |
| 86255 | 0% | 17 | $0.00 | |
| 87449 | 0% | 13 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 15 | $0.00 |
| 82945 | 0% | 17 | $0.00 | |
| 88331 | 0% | 20 | $0.00 | |
| 29130 | 0% | 12 | $0.00 | |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 0% | 95 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCMURRAY, ROBERT (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.